IRVING, Texas—LeAnn B. Smith, Executive Vice President and Chief Human Resources Officer at McKesson Corp (NYSE:MCK), recently sold 579 shares of the company's common stock. The shares were sold at a price of $602.81 each, resulting in a total transaction value of $349,026. The healthcare services giant, with a market capitalization of $76.6 billion, has shown strong momentum, trading near its 52-week high. According to InvestingPro analysis, McKesson maintains a GREAT financial health score and appears undervalued based on its Fair Value assessment.
Following this transaction, Smith holds 1,443 shares of McKesson Corp. The sale was conducted as part of a pre-established trading plan, compliant with Rule 10b5-1(c), which was adopted on September 9, 2024. The company has maintained dividend payments for 31 consecutive years, with a 14.5% dividend growth in the last twelve months. For deeper insights into McKesson's financial metrics and additional ProTips, visit InvestingPro.
In other recent news, McKesson Corporation (NYSE:MCK) has been the focus of multiple analyst reports. Mizuho (NYSE:MFG) initiated coverage on shares of McKesson with a Neutral rating, citing the company's expansion into the oncology sector and a projected 12-14% increase in earnings per share over the next three to five years. This growth strategy, bolstered by a recent analyst meeting, has sparked a rally in McKesson's shares.
On the other hand, Jefferies maintains a Buy rating for McKesson, raising its price target to $715. The firm's confidence is rooted in McKesson's focus on Oncology and Biopharma Services, the pending FCS deal's anticipated financial benefits, and the potential for Cell and Gene therapies to drive future growth.
In addition to analyst reports, McKesson has reported its second-quarter fiscal 2025 results. The earnings call, led by CEO Brian Tyler and CFO Britt Vitalone, highlighted the company's operational forecasts and future results, while acknowledging potential risks that could impact these outcomes. These recent developments offer insights into McKesson's current market position and growth potential, particularly in the oncology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.